K. Anders O. Härfstrand, M.D., Ph.D.
Dr. Härfstrand is Chair of Härfstrand Consulting AG, which he founded in 2010. Dr. Härfstrand also served as Chief Executive Officer of BBB Therapeutics BV from 2014 to 2015. Prior to that, he was President and Chief Executive Officer Europe of Makhteshim Agan Industries Ltd. from 2013 to 2014; President and Chief Executive Officer of Humabs BioMed SA from 2011 to 2012; and Chief Executive Officer of Nitec Pharma AG from 2007 to 2010. He also served in various executive and management roles at Serono, Pfizer, and Pharmacia, and in non-executive roles on a number of Supervisory Boards in Europe. He serves as the chair of the board of Brain+ (a Danish public health technology company). He served as chair of the board of each of Oasmia Pharmaceutical AB from 2020 to 2022, and Diurnal Group, plc from 2021 to 2022, and as a director of Karolinski Development AB (a biopharmaceutical investment company) from 2017 to 2019. Dr. Härfstrand earned his MD and PhD in neuropharmacology endocrinology from Karolinska Institute in Sweden. He has served on our Board since 2015.